Signal Transduction Inhibitors in the Treatment of Breast Cancer

摘要: Current systemic therapies for breast cancer are often limited by their non-specific mechanism of action, unwanted toxicities on normal tissues and short-term efficacy due to the emergence drug resistance. Identification molecular alterations in key proteins involved cell proliferation survival resulted development various signal transduction inhibitors as new treatment strategy. Preclinical data support use these agents cancer, including estrogen receptor positive patients which signalling might prevent or treat resistance endocrine therapy. These compounds have generally shown an acceptable toxicity profile. However, little clinical activity monotherapy has been reported up now. Furthermore, preliminary results trials combinations published day rather disappointing. negative findings likely occurrence mechanisms drugs.